Lynne Carty

1 Introduction Newborn screening (NBS) for Cystic Fibrosis (CF) has improved outcomes but introduces new diagnostic conundrums [1, 2]. The designation Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) -related metabolic syndrome (CRMS), known in the UK and Europe as CF Screen Positive, Inconclusive Diagnosis (CFSPID) is used for infants with a positive NBS for whom follow-up tests neither confirm, nor rule out, a CF diagnosis.

For high-security jobs like protecting military plans or corporate secrets, the last line of defense is to keep cryptographic keys and other crucial data on chips covered by elaborate physical protections, such as layers of wire mesh that will destroy the stored data if disturbed. Even this probably isn’t enough, as it turns out.

To continue reading this article, please exit incognito mode or log in. Not an Insider? Subscribe now for unlimited access to online articles. Subscribe today